Embecta Corp. EMBC
- Market cap
- $316.2M
- P/E
- 4.0×
Follow EMBC
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 23.62 | 12.72 | 9.93 | 9.20 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | 49.00 | 33.88 | 21.48 | 21.23 |
High Price
|
|||
| — | — | — | — | — | — | 1,900 | 2,200 | 2,100 | 1,850 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| — | — | — | 1,109 | 285 | 289 | 1,130 | 1,121 | 1,123 | 1,080 |
Revenue
|
|||
| — | — | — | 70.87% | 67.05% | 70.48% | 68.61% | 66.91% | 65.46% | 62.64% |
Gross Margin
|
|||
| — | — | — | 500 | 125 | 117 | 257 | 106 | 44 | 136 |
EBT
|
|||
| — | — | — | 45.09% | 43.85% | 40.30% | 22.72% | 9.43% | 3.94% | 12.62% |
EBT Margin
|
|||
| — | 0 | — | 432 | 105 | 99 | 224 | 70 | 78 | 95 |
Net Income
|
|||
| — | — | — | 36 | 9 | 8 | 35 | 39 | 49 | 60 |
Depreciation
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 19.81 | 19.58 | 19.47 | 18.53 |
Revenue/Sh
|
|||
| — | — | — | — | 7.50 | 7.28 | 3.92 | 1.23 | 1.36 | 1.64 |
Earnings/Sh
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 7.23 | 1.18 | 0.62 | 3.29 |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | 0.00 | (0.42) | (0.46) | (0.27) | (0.16) |
Capex/Sh
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 6.81 | 0.72 | 0.35 | 3.13 |
Free CF/Sh
|
|||
| — | — | — | — | 0.00 | 0.00 | (15.63) | (14.35) | (12.80) | (11.16) |
Book Value/Sh
|
|||
| — | — | — | — | 57 | 57 | 57 | 57 | 58 | 58 |
Shares
|
|||
| — | — | — | 5.22 | 5.22 | 5.22 | 7.40 | 11.94 | 10.44 | 8.66 |
PE Ratio
|
|||
| — | — | — | 2.29 | 2.29 | 2.29 | 1.45 | 0.75 | 0.72 | 0.76 |
PS Ratio
|
|||
| — | — | — | 4.87 | 4.87 | 4.87 | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | 2.29 | 2.29 | 2.29 | 2.61 | 1.92 | 1.91 | 1.87 |
EV/Sales
|
|||
| — | — | — | 6.07 | 6.07 | 6.07 | 7.61 | 52.17 | 107.74 | 11.08 |
EV/FCF
|
|||
| — | — | — | 505 | 121 | 139 | 412 | 68 | 36 | 192 |
Op' Cash Flow
|
|||
| — | — | — | (69) | (11) | (4) | (24) | (26) | (16) | (9) |
Capex
|
|||
| — | — | — | 505 | 110 | 135 | 388 | 41 | 20 | 182 |
FCF
|
|||
| — | — | — | — | 98 | 99 | 364 | 396 | 387 | 370 |
Working Cap'
|
|||
| — | — | — | — | 5 | 4 | 1,640 | 1,635 | 1,605 | 1,427 |
Total Debt
|
|||
| — | — | — | — | 5 | 4 | 1,309 | 1,308 | 1,331 | 1,198 |
Net Debt
|
|||
| — | — | — | — | 0 | 551 | (891) | (822) | (738) | (651) |
Sh' Equity
|
|||
| — | — | — | 0.00% | 0.00% | 12.93% | 24.49% | 6.12% | 6.26% | 8.03% |
ROA
|
|||
| — | — | — | — | 0.00% | 13.24% | 46.30% | 28.44% | 17.59% | 27.63% |
ROIC
|
|||
| — | — | — | 0.00% | 0.00% | 17.26% | (131.18%) | (8.22%) | (10.04%) | (13.74%) |
ROE
|
|||
Embecta Corp. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SMTI Sanara MedTech Inc. | $322.5M | 0.0× | Compare |
| OSUR OraSure Technologies, Inc. | $271.1M | 0.0× | Compare |
| UTMD Utah Medical Products, Inc. | $238.0M | 22.7× | Compare |
| PDEX Pro-Dex, Inc. | $233.9M | 17.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ZJYL Jin Medical International Ltd. | $159.2M | — | Compare |
| ANGO AngioDynamics, Inc. | $631.6M | 0.0× | Compare |
| KRMD KORU Medical Systems, Inc. | $151.0M | 0.0× | Compare |
| AVR Anteris Technologies Global Corp. | $745.6M | 0.0× | Compare |
Embecta Corp. (EMBC) key facts
- Embecta Corp. (EMBC) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- Embecta Corp.’s revenue for fiscal 2025 (year ended September 2025) was $1.1 billion, down 3.80% from fiscal 2024.
- Net income was $95.4 million, or $1.64 per share (basic), a net margin of 8.83%.
- As of September 25, 2026, EMBC traded at $5.90, a market capitalization of $316.2 million.
- At that price the stock trades at 4.0× trailing-twelve-month earnings and 0.3× sales.
- Embecta Corp. pays an annual dividend of $0.60 per share, a yield of 3.04%, with a payout ratio of 69.0%.
- Return on equity was −13.7% and debt-to-equity -2.42.
Embecta Corp. (EMBC) Latest News
14 Aug
Embecta Corp. (EMBC) conducted its Q3 2026 earnings call, covering financial results, operations and outlook. Quarterly earnings calls disclose results and guidance that can shift near-term stock sentiment and operational perceptions.
8 Aug
Embecta Corp. held Q3 2026 earnings call covering financial results, guidance and operational updates. Quarterly earnings call supplies performance data and outlook that can shift near-term investor sentiment.
7 Aug
Embecta Corp achieved strong sequential recovery in Q3 2026 and raised guidance during its earnings call. Strong sequential recovery and raised guidance signal major positive shifts in financial performance and investor outlook.
Embecta Corp. Q3 earnings call covered revenue, earnings figures, operational updates and forward guidance for the diabetes care company. Quarterly earnings data can shift near-term investor views and trading but rarely alters long-term company trajectory by itself.
Embecta Corp. released its third quarter fiscal 2026 financial results. Quarterly earnings releases provide performance data that can shift near-term investor sentiment and valuation.
15 Jul
Analysts lower Embecta (EMBC) stock fair value as medtech expectations are reset. Fair value downgrade directly pressures near-term investor sentiment and stock trajectory.
24 May
Embecta (EMBC) receives a sharp price target cut amid weakening medtech sector sentiment. Sharp analyst target cut signals reduced near-term valuation expectations for Embecta amid sector-wide sentiment decline.
18 May
Embecta Corp. (EMBC) acquires Owen Mumford for $172.6m. The $172.6 million acquisition of Owen Mumford strengthens Embecta's diabetes device portfolio and competitive positioning.
Embecta Corp. has closed its acquisition of Owen Mumford for up to $201 million. Acquisition of Owen Mumford for up to $201 million represents a major strategic expansion of Embecta's product offerings and market reach.
16 May
Embecta is resetting U.S. operations as CEO bets on GLP-1 growth and Owen Mumford diversification to drive future performance. CEO-led strategic pivot to GLP-1 and Owen Mumford diversification signals major shifts in Embecta's trajectory and investor outlook.
15 May
Embecta Corp. (EMBC) completes acquisition of Owen Mumford Holdings Limited. Acquisition represents a major strategic expansion in diabetes care devices and market reach.
14 May
S&P Global Ratings downgraded Embecta Corp. (EMBC)'s credit rating after the company reported a revenue decline. Credit rating downgrade due to revenue decline raises borrowing costs and erodes investor confidence, significantly affecting financial trajectory.
13 May
Embecta Corp. (EMBC) earnings exceed initial appearances, showing stronger underlying performance due to factors like revenue growth and margin improvements despite surface challenges. Positive earnings reassessment influences financial performance and investor sentiment moderately.
8 May
Embecta Corp. (EMBC) reported an unexpected loss, leading analysts to downgrade their forecasts for the company. Surprise loss and analyst forecast revisions indicate major pressure on Embecta's financial results and stock price.
6 May
Embecta Corp. (EMBC) conducts share buybacks amid reported losses, sparking debate on whether this reflects disciplined capital allocation or signals strategic uncertainty. Buybacks during losses may moderately influence investor sentiment and financial trajectory without fundamentally altering core operations.
5 May
Embecta Corp. (EMBC) shares plunged 27% after reporting weaker-than-expected Q1 fiscal 2025 results with revenue of $184.4 million versus $193 million forecast, adjusted EBITDA missing estimates, and slashed full-year guidance due to U.S. pricing erosion and softer international demand for insulin delivery devices. Lowered full-year guidance amid pricing pressures and demand weakness threatens significant financial strain and investor confidence.
Embecta Corp. released Q2 2026 earnings call summary detailing financial results, revenue, profitability, guidance, and strategic outlook. Quarterly earnings summaries directly shape investor sentiment, stock price, and future performance expectations.
Embecta Corp. (EMBC) released Q2 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Earnings transcripts disclose quarterly financials, strategic updates, and guidance that drive stock volatility and investor decisions.
Embecta Corp. (EMBC) released Q2 earnings call highlights detailing financial results, operational updates, and future outlook. Q2 earnings highlights cover financial performance and guidance that significantly influence investor sentiment and stock trajectory.
Embecta Corp. reports second quarter fiscal 2026 financial results. Quarterly earnings reports like Q2 fiscal 2026 results typically drive significant stock volatility and shape investor expectations for future performance.
15 Apr
Embecta Corp. (EMBC) investment story shifts as fair value estimates and investor expectations undergo significant reset, prompting reevaluation of the company's outlook and market positioning. Fair value reset and shifting expectations represent major changes in market dynamics and investor sentiment that could significantly alter Embecta's trajectory.
23 Mar
Embecta Corp. (EMBC) plans to acquire Owen Mumford to expand its drug-delivery portfolio. Acquisition of Owen Mumford strategically expands Embecta's drug-delivery capabilities, significantly enhancing its competitive position and growth prospects.
20 Mar
Embecta Corp. (EMBC) agrees to acquire Owen Mumford, a maker of medical devices including safety needles and lancets for diabetes care. Agreement to acquire Owen Mumford enables strategic expansion in diabetes care devices, boosting Embecta's product portfolio and competitive position.
Embecta Corp. (EMBC) agrees to acquire Owen Mumford, a maker of medical devices including pen needles for diabetes care. Agreement to acquire Owen Mumford enables Embecta to expand its diabetes care portfolio and strengthen competitive positioning.
19 Mar
Embecta Corp. (EMBC) to acquire Owen Mumford for up to $201 million. Acquisition of Owen Mumford for up to $201M is a major strategic move expanding Embecta's diabetes care portfolio and market reach.
Embecta Corp. announces definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device manufacturer specializing in safety needles, lancets, and pen needles, to expand its diabetes care portfolio and enhance global market presence. Acquisition of Owen Mumford bolsters Embecta's diabetes device offerings and competitive edge through synergistic product expansion.
12 Feb
Embecta Corp. (NASDAQ: EMBC) reported solid earnings that analysts believe are understated, indicating potential for future growth. The company's performance reflects strong demand for its products, particularly in the diabetes management sector. Analysts suggest that the market may not fully appreciate the company's earnings potential, which could lead to upward adjustments in stock valuation. Overall, Embecta's financial health appears robust, positioning it well for continued success in a competitive landscape. Strong earnings performance and potential market undervaluation suggest significant future impact on the company's trajectory.
11 Feb
Embecta Corp. has appointed a new Chairman of the Board and Lead Independent Director, signaling a shift in leadership. The company aims to enhance its governance and strategic direction with these new appointments, which are expected to strengthen its position in the market. Leadership changes can moderately influence the company's strategic direction and market positioning.
6 Feb
Embecta Corp. (EMBC) is highlighted among the top healthcare stocks for 2026 due to its high dividend payouts. The company is recognized for its commitment to returning value to shareholders through consistent dividend payments, making it an attractive option for income-focused investors. As the healthcare sector continues to evolve, Embecta's financial strategies and dividend policies position it favorably in the market. Embecta's high dividend yield may influence investor sentiment and financial performance but is not expected to fundamentally alter its trajectory.
5 Feb
Embecta Corp. reported its Q1 earnings, highlighting a revenue increase driven by strong demand for its diabetes management products. The company emphasized its commitment to innovation and expanding its product portfolio. Management provided insights into operational efficiencies and strategic initiatives aimed at enhancing market presence. Future guidance indicates optimism for continued growth, supported by ongoing investments in technology and customer engagement. Significant growth in revenue and strategic initiatives suggest a strong potential for future performance.